David S. Ege - 27 Apr 2023 Form 4 Insider Report for Seres Therapeutics, Inc. (MCRB)

Signature
/s/ Thomas J. DesRosier, attorney-in-fact for David S. Ege
Issuer symbol
MCRB
Transactions as of
27 Apr 2023
Net transactions value
-$36,527
Form type
4
Filing time
01 May 2023, 16:46:25 UTC
Previous filing
07 Feb 2023
Next filing
31 Oct 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MCRB Common stock Award $0 +20,000 +43% $0.000000 66,734 27 Apr 2023 Direct F1
transaction MCRB Common stock Sale $36,527 -7,038 -11% $5.19 59,696 28 Apr 2023 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On May 3, 2021, the reporting person was granted an award of 40,000 restricted stock units, which vested in the form of shares of the Issuer's common stock in two equal installments upon the satisfaction of certain performance criteria. On April 27, 2023, the Issuer's Board of Directors determined that the performance criteria for the second installment were met, resulting in the vesting and settlement of the award as to 20,000 shares.
F2 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on May 3, 2021, solely with the intent to cover taxes in connection with the vesting of the restricted stock units.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.0350 to $5.1900, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

Executive Vice President and Chief Technology Officer